Pharma Industry warns minimum import prices plan could raise drug prices, hurt MSMEs

Pharma experts have flagged concerns over the government’s plan to set minimum import prices (MIP) for key drug ingredients such as Penicillin-G, 6APA and amoxicillin. They warn this will raise manufacturing costs, increase medicine prices and hurt over 10,000 MSMEs, potentially causing major job losses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UrBJILh
via IFTTT